Capital World Investors Decreases Holdings in Novo Nordisk A/S (NYSE:NVO)

Capital World Investors decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,446,019 shares of the company's stock after selling 7,997 shares during the quarter. Capital World Investors owned 0.10% of Novo Nordisk A/S worth $382,381,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Victory Capital Management Inc. grew its holdings in shares of Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock valued at $5,482,000 after buying an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after buying an additional 30,420 shares during the period. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $86,000. Finally, Talbot Financial LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $4,066,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 1.9 %

NVO traded up $1.19 during midday trading on Thursday, reaching $62.49. The company's stock had a trading volume of 4,495,891 shares, compared to its average volume of 8,927,541. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The stock's 50-day moving average is $74.34 and its 200-day moving average is $90.56. The firm has a market capitalization of $280.43 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 0.90 and a beta of 0.61. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a $0.7874 dividend. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is 49.54%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, April 15th. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.